Drug Discovery World

NOVEMBER 30, 2022

Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response. .

Production 130

Production Immune Response RNA Drugs 130

Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Discovery World

JULY 8, 2024

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. However, the RNA landscape has drastically changed in recent years and we now know that the molecule is more than just a transient, linear carrier of information.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

MARCH 8, 2022

The study was published online in advance in the journal Molecular Therapy – Nucleic Acids and is now available in the final version. Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA. Camouflage protects virus from immune system. doi: 10.1016/j.omtn.2022.02.008.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

DrugBank

MAY 15, 2024

Another promising avenue is the use of technologies like RNA interference and gene editing, which allow scientists to turn off the production of certain proteins altogether. 5 This period also saw the rise of biologics in the 1980s, which have played a crucial role in modern therapies, particularly for diseases like cancer.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. CHENGDU, China , Feb. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Target Review

FEBRUARY 5, 2024

Using RNA sequencing to identify the proteins these cells secrete, they discovered that the macrophages from bone marrow responded differently on their own to interferon gamma, a protein produced by cells in response to infection, and lipopolysaccharide, a molecule found in some bacteria that stimulates the immune system.

Laboratories 59

Laboratories Immune Response Regulations RNA 59

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 130

RNA Vaccine Drugs Disease 130

Broad Institute

DECEMBER 6, 2023

The reference, called the Immune Dictionary , appears today in Nature. Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. For many immune-mediated diseases, there's no cure or treatment.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Sanofi’s two marketed extended half-life factor replacement therapies shifted a two-decades-old treatment paradigm when launched in 2014. ePoster.

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. “As

Disease 142

Disease Therapies Engineering Clinical Trials 142

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. link] 1. About ImmunityBio.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Drug Target Review

APRIL 3, 2024

Our company has identified a new role for Growth Differentiation Factor 15 (GDF-15) as a potent local immunosuppressor mediating cancer resistance to therapy. I am currently working as Chief Scientific Officer at CatalYm, where we translate the latest scientific findings into clinical applications. in North America) in late 2017.

Science 105

Science Clinical Development DNA Treatment 105

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

Drug Discovery World

JUNE 27, 2023

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer therapies.

Therapies 130

Therapies Immune Response Regulations RNA 130

Drug Target Review

MARCH 21, 2024

There are a few approved therapies for DMD including four exon-skipping drugs and one AAV-microdystrophin drug, which uses a shortened version of dystrophin. AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. Of note, mRNA is redosable as opposed to AAV.

Therapies 64

Therapies RNA Immune Response Production 64

SugarCone Biotech

MAY 28, 2019

Lymphoid Structures Drive Immune Checkpoint Therapy and the Efficacy of Cellular Therapeutics (a reboot from 2020) We’d been hearing the rumors for months. is focused on the response of sarcomas to immunotherapy ( [link] ). These observations suggest that B cells and TLS are important for successful ICB therapy.

Immune Response 52

Immune Response Therapies Production Vaccine 52

Codon

JULY 27, 2023

Their cone cells, which are responsible for color vision, don’t work like normal. But what happens if you restore these cone cells, using gene therapy? approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

Their cone cells, which are responsible for color vision, don’t work like normal. But what happens if you restore these cone cells, using gene therapy? approved a gene therapy for hemophilia A for the first time. The therapy works by replacing beta-cells with “fresh” cells taken from a, err…dead person.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.

Bioinformatics 130

Bioinformatics RNA Vaccine Clinical Trials 130

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.

RNA 128

RNA Immune Response Therapies Disease 128

Drug Discovery World

APRIL 12, 2023

Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.

Vaccine 130

Vaccine Immune Response RNA DNA 130

Drug Discovery World

JANUARY 4, 2023

“This triple combination therapy led to an unprecedented curative response in our models,” said corresponding author Ronald DePinho, Professor of Cancer Biology. The researchers used high-dimensional immune profiling and single-cell RNA sequencing to study how the TIME is affected by a variety of immunotherapies.

Immune Response 130

Immune Response Therapies RNA Clinical Trials 130

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. Immunopheresis is a ‘subtractive therapy,’ in contrast to alternative drugs that constitute ‘additive’ therapies.

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Broad Institute

OCTOBER 11, 2023

His mother had a presentation of the disease that suggested her immune system was already on the job. But immunotherapy was not yet widely used and had not been applied clinically to Merkel cell carcinoma, so she received traditional chemotherapy and radiation therapy, suffering life-threatening complications along the way.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

Drug Discovery World

OCTOBER 6, 2022

Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies.

Clinical Trials 130

Clinical Trials Immune Response Therapies Trials 130

Codon

APRIL 9, 2023

” — Harold Morowitz 🔥 Ten Amazing Things (that happened this week…) A CAR-T therapy was tested in 27 children with neuroblastomas. Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. Molecular Therapy. Gene Therapy.

Therapies 52

Therapies RNA Engineering Vaccine 52

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. But the printed vaccines are very good! vander Straeten et al. Synthetic Biology. Cell Systems.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. But the printed vaccines are very good! vander Straeten et al. Synthetic Biology. Cell Systems.

Vaccine 52

Vaccine Engineering DNA RNA 52

Drug Discovery World

DECEMBER 15, 2022

Early phase clinical trials for gene editing therapies. Numerous early phase clinical trials of potential gene editing therapies have emerged over the past five years. Prime editing, while also employing a single strand nick, expands this scope to all 12 possible changes using a more complex prime editing guide RNA (pegRNA).

DNA 130

DNA Clinical Trials Therapies RNA 130

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.

Vaccine 52

Vaccine RNA Clinical Trials Immune Response 52